Lymphoma Clinical Trial
— IMPACTOfficial title:
A Clinic-Based Interdisciplinary Intervention for Parents of Children With Cancer
Verified date | April 2022 |
Source | Children's Hospital Medical Center, Cincinnati |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test the efficacy of a clinic-based intervention designed to reduce illness uncertainty for parents of children who have been recently diagnosed with cancer.
Status | Completed |
Enrollment | 279 |
Est. completion date | February 1, 2022 |
Est. primary completion date | April 22, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility | Inclusion Criteria: - The child has been diagnosed with leukemia or lymphoma, malignant solid tumor, or malignant brain tumor - The child is being treated for cancer and returning to the medical center (CCHMC or OUHSC). - The child is 18 years of age or younger - Recruitment occurs within 2-12 weeks post diagnosis - The parent is responsible for care and is willing to give consent and participate - The child is willing to give assent or consent and participate (only for children 8 years old and older) - The parent gives patient permission to participate. - Parent is fluent in English Exclusion Criteria: - The child is experiencing an imminent medical crisis necessitating significant medical intervention - The child with cancer is determined to be in the terminal phase of illness and/or is receiving end of life care - The diagnosis is determined to be a relapse or a second malignancy - The parent is currently being treated for a serious psychiatric disorder, or, evidences mental retardation - The parent is younger than 18 years of age - The parent is not English speaking - The parent is unwilling to give written permission for child participation - If the patient's treatment visit schedule is too infrequent to meet the study visit timeline requirements |
Country | Name | City | State |
---|---|---|---|
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Dayton Children's Hospital | Dayton | Ohio |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital Medical Center, Cincinnati | Dayton Children's Hospital, Oklahoma State University, University of Oklahoma |
United States,
Basile NL, Chardon ML, Peugh J, Edwards CS, Szulczewski L, Morrison CF, Nagarajan R, El-Sheikh A, Chaney JM, Pai ALH, Mullins LL. Relationship Between Caregiver Uncertainty, Problem-Solving, and Psychological Adjustment in Pediatric Cancer. J Pediatr Psyc — View Citation
Marsolo K, Shuman W, Nix J, Morrison CF, Mullins LL, Pai AL. Reducing Parental Uncertainty Around Childhood Cancer: Implementation Decisions and Design Trade-Offs in Developing an Electronic Health Record-Linked Mobile App. JMIR Res Protoc. 2017 Jun 26;6( — View Citation
Morrison CF, Szulczewski L, Strahlendorf LF, Lane JB, Mullins LL, Pai AL. Designing Technology to Address Parent Uncertainty in Childhood Cancer. ANS Adv Nurs Sci. 2016 Jan-Mar;39(1):15-25. doi: 10.1097/ANS.0000000000000100. — View Citation
Sharkey CM, Schepers SA, Drake S, Pai ALH, Mullins LL, Grootenhuis MA. Psychosocial Risk Profiles Among American and Dutch Families Affected by Pediatric Cancer. J Pediatr Psychol. 2020 May 1;45(4):463-473. doi: 10.1093/jpepsy/jsaa012. — View Citation
Szulczewski L, Mullins LL, Bidwell SL, Eddington AR, Pai ALH. Meta-Analysis: Caregiver and Youth Uncertainty in Pediatric Chronic Illness. J Pediatr Psychol. 2017 May 1;42(4):395-421. doi: 10.1093/jpepsy/jsw097. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Psychosocial Functioning as assessed by the global severity index (GSI) of the symptom checklist 90. | indicator of global psychological symptoms | Change in (global severity index) GSI score from baseline to 1-week post-intervention | |
Primary | Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90. | indicator of global psychological symptoms | Change in GSI score from baseline to 3-month post-intervention | |
Primary | Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90. | indicator of global psychological symptoms | Change in GSI score from baseline to 6-month post-intervention | |
Primary | Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90. | indicator of global psychological symptoms | Change in GSI score from baseline to 12-month post-intervention | |
Secondary | Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) | Measure of caregiver post-traumatic stress symptoms | Change in IES-R total score score from baseline to 1-week post-intervention | |
Secondary | Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) | Measure of caregiver post-traumatic stress symptoms | Change in IES-R total score score from baseline to 3-month post-intervention | |
Secondary | Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) | Measure of caregiver post-traumatic stress symptoms | Change in IES-R total score score from baseline to 6-month post-intervention | |
Secondary | Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) | Measure of caregiver post-traumatic stress symptoms | Change in IES-R total score score from baseline to 12-month post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |